1502 related articles for article (PubMed ID: 18996393)
1. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
2. The effect of R249S carcinogenic and H168R-R249S suppressor mutations on p53-DNA interaction, a multi scale computational study.
Rauf SM; Ismael M; Sahu KK; Suzuki A; Koyama M; Tsuboi H; Hatakeyama N; Endou A; Takaba H; Del Carpio CA; Kubo M; Miyamoto A
Comput Biol Med; 2010 May; 40(5):498-508. PubMed ID: 20403587
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.
Nikolova PV; Wong KB; DeDecker B; Henckel J; Fersht AR
EMBO J; 2000 Feb; 19(3):370-8. PubMed ID: 10654936
[TBL] [Abstract][Full Text] [Related]
4. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein.
Martin AC; Facchiano AM; Cuff AL; Hernandez-Boussard T; Olivier M; Hainaut P; Thornton JM
Hum Mutat; 2002 Feb; 19(2):149-64. PubMed ID: 11793474
[TBL] [Abstract][Full Text] [Related]
5. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
6. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal A; Rotter V
Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
[TBL] [Abstract][Full Text] [Related]
8. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations.
Joerger AC; Ang HC; Veprintsev DB; Blair CM; Fersht AR
J Biol Chem; 2005 Apr; 280(16):16030-7. PubMed ID: 15703170
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
[TBL] [Abstract][Full Text] [Related]
11. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
12. The effect of mutations on peptide models of the DNA binding helix of p53: evidence for a correlation between structure and tumorigenesis.
Trulson JA; Millhauser GL
Biopolymers; 1999 Mar; 49(3):215-24. PubMed ID: 9990839
[TBL] [Abstract][Full Text] [Related]
13. Specific binding of MAR/SAR DNA-elements by mutant p53.
Müller BF; Paulsen D; Deppert W
Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.
Bullock AN; Henckel J; Fersht AR
Oncogene; 2000 Mar; 19(10):1245-56. PubMed ID: 10713666
[TBL] [Abstract][Full Text] [Related]
15. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.
Forrester K; Lupold SE; Ott VL; Chay CH; Band V; Wang XW; Harris CC
Oncogene; 1995 Jun; 10(11):2103-11. PubMed ID: 7784055
[TBL] [Abstract][Full Text] [Related]
16. In vitro structure-function analysis of the beta-strand 326-333 of human p53.
Chène P; Mittl P; Grütter M
J Mol Biol; 1997 Nov; 273(4):873-81. PubMed ID: 9367778
[TBL] [Abstract][Full Text] [Related]
17. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
[TBL] [Abstract][Full Text] [Related]
18. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
19. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
20. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
Kubicka S; Trautwein C; Niehof M; Manns M
Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
